Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness.
Fibrocystic breast conditions, formerly referred to as fibrocystic breast disease, affect about half of all women and typically present as any combination of breast nodularity, swelling, and pain. We reviewed the literature to evaluate evidence supporting nutrition interventions commonly recommended for fibrocystic breast conditions by health care providers. Randomized, controlled studies of the effectiveness of caffeine restriction fail to support any benefit in fibrocystic breast conditions. Similarly, evidence supporting evening primrose oil, vitamin E, or pyridoxine as treatments for the discomforts of fibrocystic breast conditions is insufficient to draw conclusions about effectiveness. Dietary alterations that influence the intermediate markers for fibrocystic breast conditions include low-fat (15% to 20% energy), high-fiber (30 g/day), and soy isoflavone regimens. However, our findings provide no solid evidence for secondary prevention or treatment of fibrocystic breast conditions through a dietary approach. Health care providers should limit recommendations to proven diet therapies supported by randomized, placebo-controlled trials, given the instability inherent in fibrocystic breast conditions and the near 20% placebo effect associated with intervention. Because excessive estrogen or altered sensitivity to estrogen is the dominant theory of etiology, interventions that may modulate endogenous steroid hormones warrant further investigation as potential treatments for symptomatic fibrocystic breast conditions.
Horner
N K
NK
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Lampe
J W
JW
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002110:Caffeine / Q000009:adverse effects; D018752:Diet, Fat-Restricted; D004041:Dietary Fats / Q000009:adverse effects; D004043:Dietary Fiber / Q000627:therapeutic use; D005228:Fatty Acids, Essential / Q000627:therapeutic use; D005260:Female; D005348:Fibrocystic Breast Disease / Q000178:diet therapy* / Q000209:etiology; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use; D008041:Linoleic Acids; D016239:MEDLINE; D031665:Oenothera biennis; D010938:Plant Oils; D011736:Pyridoxine / Q000627:therapeutic use; D016896:Treatment Outcome; D014810:Vitamin E / Q000627:therapeutic use; D014970:Xanthines / Q000009:adverse effects; D017965:gamma-Linolenic Acid
D000970:Antineoplastic Agents; D004041:Dietary Fats; D004043:Dietary Fiber; D005228:Fatty Acids, Essential; D007529:Isoflavones; D008041:Linoleic Acids; D010938:Plant Oils; D014970:Xanthines; D014810:Vitamin E; C008514:methylxanthine; D002110:Caffeine; C028498:evening primrose oil; D017965:gamma-Linolenic Acid; D011736:Pyridoxine